Short communication: Amitraz treatments do not increase the frequency of mutations in the β2-adrenergic octopamine receptor in Varroa destructor: a field study in Central Spain

Key Points

• No increase in β2-adrenergic octopamine receptor mutations was observed from amitraz treatments.
• Testing revealed no significant mutations in Varroa destructor after exposure to amitraz in the field.
• Field study conducted in Central Spain assessed the genetic effects of amitraz on the target species.
• Findings imply that amitraz use may be safe regarding genetic mutation risks for Varroa destructor.